Taipei,, March 14, 2025 / Prnewswire / – Cordycepts Sunshine Biotech Holdings Co., Ltd. 【CS group】in collaboration with the Research and development association of the Chinese Mushroom Industry (CHFIRDA)hosted on “Taiwanofungus pharmacological applications camphoratus on the pet market” In Taipei. During the event, 【CS group】 officially announced its latest research results, revealing that Antcin hasA purified extract from Taiwanofungus camphoratus, demonstrates the potential Synergic effects with traditional steroids.
The company also explores partnerships with PREMIUM pet food brands in China and plans to present Extracts exclusively provided Taiwanofungus Camphoratus through his Great China distributer, Agricultural biotechnology of Guangdong BaoquanAs part of its strategy to develop on the high -end pet food market.
Acceleration of the marketing of Taiwanofungus Camphorates based on pharmaceuticals based
Doctor Jia-Xin HuangA leading expert in Taiwanofungus camphoratus,, stressed that development New biopharmaceuticals Traditionally, an in -depth investment in animal and human tests, without guarantee of success. However, Taiwanofungus camphoratus has already been widely sought after, providing a solid scientific base without the need to start from scratch.
A key concern in previous discussions was long -term use of Traditional steroids,, which often leads to Damage caused by the liver and kidneys as a side effect. Taiwanofungus camphoratus is known for his Liver and kidney protection properties,, encourage other studies on its potential to reduce the harmful effects of steroids without compromising the efficiency.
To validate this hypothesis, 【CS group】 conducted an experience combining its owner extract of TF-15 Taiwanofungus camphoratus with steroid dexamethasone (DXM) in models of lung cancer cells. The study confirmed:
- The genetic verification of the TF-15 confirmed its authenticity 【CS group】As a Taiwanofungus camphoratus.
- The TF-15 has a power comparable to the fruiting bodies of Taiwanofungus cultural camphoratus.
- A high concentration of Antcin A has been successfully extracted by a process of purification at several stages.
- The combination of Antcin A and Dexamethasone has shown potential synergistic effects in the reduction and inversion of the growth of cancer cells.
Recognize the regulatory and marketing advantages of veterinary applications, 【CS group】 prioritizes preclinical tests for pet medicine. The strategy includes:
- Establish a safe dose and petulations for pets, such as oral solutions and baking tablets.
- Accelerate human clinical trials by taking advantage of veterinary data.
- Expand applications to TEP and Humans nutraceuticals, offering a flexible market strategy.
This approach offers a balanced and strategic entry into the pharmaceutical sector, positioning Taiwanofungus camphoratus as a viable candidate for integrated health and human health solutions.
Vincent LiuDirector of technology at 【CS group】underlined the significant growth potential in China Pet market. In 2024, China The animal population reached 124.1 million, the pet food industry evaluated to $ 22.2 billions, including $ 9.8 billion in cat food and $ 10.3 billion in dog food. While mature markets like North America And Europe have penetration rates above 90%, China Market penetration is still around 20%, reporting a substantial place for growth.
According to China Feed Industry Association (CIRA), there are approximately 200 certified pet food manufacturers in pet ChinaWith a total annual production capacity of 1.12 million tonnes. The market moves to a premium brand, creating opportunities for high -end functional pet food. 【CS group】 actively engages with China the main brands of leading pet food and, through its Great China Distributor, Guangdong Baoquan Agricultural Biotechnology, plans to integrate extracts from Taiwanofungus camphoratus in food formulations for premium pets.
Beyond pet nutrition, veterinary pharmaceutics have another growth avenue. The global market for pharmaceutical products includes treatments for external and internal parasites, allergic dermatitis, relief of anti-inflammatory pain, anti-nausea, insulin, antibiotics and heart failure management. Given the broad -spectrum bioactivity of Taiwanofungus camphoratus, its potential therapeutic applications in pet medicine are very promising.
Huang roadPresident of 【CS group】highlighted the importance of high quality culture to ensure premium product yields. He underlined the company’s commitment to optimize the selection and mass production of Taiwanofungus camphoratus, allowing an effective extraction and purification of bioactive compounds for pharmaceutical applications.
“The effectiveness of Antcin A is well established in the industry, but the real question is: who has the capacity to direct the market in large -scale extraction and production?” Huang said. “The one who masters mass production of extracts from Taiwanofungus camphoratus will control the next phase of the industry.”
While the company has ambitious objectives, Huang stressed the importance of feasible milestones. Based on DR Jia-Xin Huang’s preliminary conclusions, 【CS group】 has already made exciting progress and is optimistic that an additional optimization will lead to the development of the first batch of veterinary pharmaceutical products based on Taiwanofungus camphoratus. This breakthrough has the potential to accelerate marketing and integration into the pet health industry.
With scientific validation, strategic partnerships and market positioning, 【CS group】 Adjusts Taiwanofungus Camphoratus from traditional applications to new generation pharmaceuticals. While the global health and human health industries continue to develop, the company is well placed to direct innovation in functional ingredients and biopharmaceutical applications.
Show original content to download the multimedia:https://www.prnewswire.com/apac/News-releases/cs-group-antcin-and-steroid-combination-shows-synergistic-potential-in-préliminaire-study-302401048.html
Source Cordycepts Sunshine
